AbbVie increased its quarterly dividend by 5.5% to $1.73 per share even as its flagship drug Humira faces steep revenue declines due to patent expirations. Despite Humira's sales dropping 36.1% in Q2 2026 and nearly 50% in 2025, AbbVie's strong free cash flow and growing sales from newer drugs like Skyrizi and Rinvoq support the dividend growth. The company faces challenges with high leverage and upcoming patent expirations on newer drugs but remains confident in its pipeline and long-term dividend sustainability. Investors see AbbVie as fairly valued given its steady dividend and growth prospects amid the patent transition.
AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, dr...
AbbVie announced positive Phase 3 results for etentamig, a BCMA x CD3 bispecific T-cell engager, in treating triple-class exposed relapsed/refractory multiple myeloma. The CERVINO study showed etentamig achieved a 74% objective response rate and a 60...
AbbVie has finalized its $10.9 billion acquisition of Apogee Therapeutics, enhancing its immunology portfolio with Apogee's late-stage drug candidates targeting inflammatory diseases like atopic dermatitis and asthma. Apogee's lead asset, zumilokibar...
AbbVie announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company's management will engage in a fireside chat at 9:00 a.m. Central time, which will be accessible via a live audio we...
JPMorgan's JEPI ETF offers an 8.33% yield mainly from option premiums and large-cap stocks, but in taxable accounts, most distributions are taxed as ordinary income, not at the lower qualified dividend rate. This results in a significant tax penalty—...
